MARKET

ABEO

ABEO

Abeona
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.080
+0.120
+6.12%
After Hours: 2.080 0 0.01% 17:26 09/18 EDT
OPEN
2.200
PREV CLOSE
1.960
HIGH
2.335
LOW
2.045
VOLUME
3.29M
TURNOVER
--
52 WEEK HIGH
5.19
52 WEEK LOW
1.350
MARKET CAP
176.34M
P/E (TTM)
-1.5889
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average ABEO stock price target is 8.63 with a high estimate of 16.00 and a low estimate of 4.000.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ABEO
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Abeona Therapeutics Inc stock information, including NASDAQ:ABEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABEO stock methods without spending real money on the virtual paper trading platform.